Brought to you by 
Alzheimer’s start-up Alzheon raises undisclosed amount in Series A financing; closes at $10mm
08 Apr 2015
Executive Summary
Concurrent with the neurodegenerative disease start-up’s launch, Alzheon Inc. completed a Series A financing, raising an undisclosed amount from private backers. The company also in-licensed its first candidate, a Phase I prodrug of tramiprosate for Alzheimer’s disease, plus other IP from Bellus Health. Earlier this year, Alzheon sold $550k worth of notes and other rights to eight investors, according to a Form D filing.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alzheimer’s start-up Alzheon raises undisclosed amount in Series A financing; closes at $10mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice